Anthony Recupero Sells 3,833 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) insider Anthony Recupero sold 3,833 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $17.44, for a total transaction of $66,847.52. Following the completion of the transaction, the insider directly owned 268,144 shares in the company, valued at $4,676,431.36. This trade represents a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

SiBone Stock Up 1.3%

NASDAQ SIBN traded up $0.24 during trading on Wednesday, reaching $18.60. The company’s stock had a trading volume of 472,223 shares, compared to its average volume of 442,797. The stock has a market capitalization of $807.05 million, a PE ratio of -36.47 and a beta of 0.81. The business has a 50-day moving average price of $15.40 and a 200-day moving average price of $16.72. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21. SiBone has a 1-year low of $11.70 and a 1-year high of $20.05.

SiBone (NASDAQ:SIBN) last posted its earnings results on Monday, November 10th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. The firm had revenue of $48.66 million for the quarter, compared to the consensus estimate of $46.67 million. SiBone has set its FY 2025 guidance at EPS. On average, research analysts forecast that SiBone will post -0.78 earnings per share for the current fiscal year.

Institutional Trading of SiBone

A number of institutional investors and hedge funds have recently modified their holdings of SIBN. ANTIPODES PARTNERS Ltd acquired a new stake in SiBone in the first quarter worth $34,000. State of Alaska Department of Revenue acquired a new position in shares of SiBone during the third quarter worth about $39,000. State of Wyoming bought a new position in shares of SiBone during the 2nd quarter worth approximately $55,000. Virtus Advisers LLC bought a new position in SiBone in the first quarter valued at $58,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of SiBone in the second quarter valued at about $68,000. 98.11% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SIBN. Cantor Fitzgerald set a $25.00 price target on shares of SiBone and gave the stock an “overweight” rating in a research report on Monday, August 11th. Wall Street Zen downgraded shares of SiBone from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a report on Wednesday, October 8th. Finally, Truist Financial lowered their price target on SiBone from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $23.00.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.